10-Q: Impact BioMedical Reports First Quarter 2024 Results, Net Loss Increases Amidst IPO Preparations

Impact BioMedical's first quarter 2024 results show an increased net loss compared to the same period last year, primarily due to costs associated with its initial public offering.

Summary

• Impact BioMedical reported a net loss of $998,000 for the three months ended March 31, 2024, compared to a net loss of $849,000 for the same period in 2023.
• The increased loss is primarily attributed to higher sales, general, and administrative compensation costs related to the company's registration with the SEC and NYSE American.
• Research and development expenses decreased significantly due to the cessation of a contract with GRDG.
• The company's total costs and expenses were $771,000 for the quarter, a slight decrease from $803,000 in the prior year.
• Interest expense increased due to a higher outstanding debt balance with DSS, a related party.
• The company's cash position remains low at $2,000 as of March 31, 2024, but they believe they have sufficient access to funds through a revolving promissory note with DSS.
• Impact BioMedical is focused on developing and commercializing solutions for medical advances in human wellness and healthcare, including drug discovery and alternative sugar and fragrance technologies.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with increased losses and low cash reserves, but also highlights the company's efforts to go public and develop innovative technologies. The overall sentiment is cautiously negative due to the financial challenges.

Positives

• The company has been approved for listing on the NYSE American exchange, which could provide access to capital.
• The company has a revolving promissory note with DSS, which provides access to capital.
• The company is developing several promising technologies, including a universal therapeutic drug platform, a low-calorie sugar substitute, and a mosquito-repelling fragrance.

Negatives

• The company experienced an increased net loss of $998,000 in Q1 2024 compared to $849,000 in Q1 2023.
• The company's cash balance is very low at $2,000 as of March 31, 2024.
• The company is reliant on debt financing from a related party, DSS.
• The company's disclosure controls and procedures were deemed not effective as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and monetize its intellectual properties.
• The company's business is subject to risks inherent in the establishment of a new business enterprise, including delays in research, testing, and marketing efforts.
• The company is dependent on a related party, DSS, for funding through a revolving promissory note.
• The company's disclosure controls and procedures were not effective as of March 31, 2024, which could lead to inaccurate financial reporting.
• The company has a history of operating losses and negative cash flows.

Future Outlook

The company intends to continue as a going concern through monetization of its intellectual properties, controlling operating costs, and raising additional capital through an initial public offering.

Management Comments

• The company's management believes that it has sufficient availability to cash via its revolving promissory note with DSS to meet its cash requirements for at least the next 12 months.
• Management intends to take actions necessary to continue as a going concern, including monetization of intellectual properties and tightly controlling operating costs.

Industry Context

The company operates in the competitive biohealth and biomedical fields, focusing on drug discovery and the development of innovative health solutions. The company's focus on multiple disease targets and alternative health products aligns with current trends in the industry.

Comparison to Industry Standards

• The company's financial performance is not directly comparable to established pharmaceutical companies due to its early stage of development and lack of significant revenue.
• The company's reliance on debt financing from a related party is not typical of larger, more established companies in the industry.
• The company's focus on licensing and distribution through its ecosystem is a unique approach compared to traditional pharmaceutical development models.
• The company's research and development expenses are lower than many companies in the pharmaceutical industry, reflecting its focus on early-stage development and licensing.

Related Party Transactions

• The company has a significant note payable to DSS, a related party.
• DSS incurs general and administrative costs on behalf of the company, which are passed through monthly.
• The company had a research and development agreement with GRDG, a related party, which was terminated in 2023.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and low cash reserves.
• Employees may be impacted by the company's efforts to control operating costs.
• Customers and partners may be interested in the company's progress in developing and commercializing its technologies.
• Creditors, particularly DSS, are significant stakeholders due to the company's debt obligations.

Next Steps

• The company will continue to pursue its initial public offering.
• The company will focus on monetizing its intellectual properties.
• The company will continue to control operating costs.
• The company will continue to develop and commercialize its technologies.

Key Dates

Keywords

biomedical, pharmaceutical, drug discovery, neurological, oncological, immunological, Laetose, sugar substitute, fragrance, Equivir, antiviral, IPO, NYSE American, intellectual property, licensing